Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Dapagliflozin
Warfarin
Digoxin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
- Body Mass Index (BMI) of 18 to 32 kg/m², inclusive. BMI = weight (kg)/ [height (m)]²
- Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) and men, ages 18 to 45
Exclusion Criteria:
- WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal
- Any significant acute or chronic medical illness or relevant trauma (e.g. history of chronic hypertension, bacterial endocarditis, hemorrhagic stroke, motor vehicle accident resulting in significant head trauma or internal injuries)
- History of important arrhythmias as determined by the Investigator, including but not limited to ventricular fibrillation, ventricular tachycardia, A-V block, Wolff-Parkinson-White Syndrome, and sinus bradycardia (defined in this study as heart rate < 50 bpm based on vital signs and ECG performed within 21 days of Study Day 1)
- History or evidence of abnormal bleeding or coagulation disorder (e.g., history of prolonged bleeding during dental procedures, pregnancy delivery, previous surgery or injury) and/or having a first degree relative under 50 years of age with a history of abnormal bleeding or coagulation disorder per patient's report
- History of unexplained syncope
- Presence of external hemorrhoids with signs of rectal bleeding on physical exam
- Positive fecal occult blood (FOB), using the Hemoccult Sensa® assay (or equivalent), or hematuria (more than trace), unless deemed not clinically significant by the Investigator and Medical Monitor at screening or dosing
- Platelet count < 150,000 cells/µL at screening or dosing
- INR or aPTT values above the upper limit of normal (ULN) at screening or dosing
- Hemoglobin or hematocrit < LLN at screening or dosing
- Abnormal urinalysis at screening or dosing (repeat urinalysis may be allowed for positive hematuria in women)
- Glucosuria at screening or dosing
- Abnormal liver functions tests (ALT, AST or total bilirubin > 10% above ULN) at screening or dosing
- History of diabetes mellitus
- History of heart failure
- History of renal insufficiency
- History of recurrent (defined as 3 occurrences per year) or recent vulvovaginal mycotic infections
- Positive urine screen for drugs of abuse either at screening or before dosing
- Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1, -2 antibody
- Protein C or Protein S deficiency
- History of allergy to SGLT2 inhibitors or related compounds
- History of allergy to warfarin or related compounds
- History of allergy to digoxin or related compounds
- Prior exposure to dapagliflozin within 3 months of Day -1
- Exposure to any investigational drug or placebo within 4 weeks of Day -1
- Use of any prescription drugs within or over-the-counter acid controllers or vitamin K containing products within 4 weeks prior to study drug administration
Sites / Locations
- Pra International
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Arm Label
Dapagliflozin + Warfarin
Warfarin
Dapagliflozin + Digoxin
Digoxin
Arm Description
Outcomes
Primary Outcome Measures
Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs
Secondary Outcome Measures
To assess the effect of dapagliflozin on the PK of R-warfarin, when warfarin and dapagliflozin are coadministered in healthy subjects (Cohort 1)
To assess the safety and tolerability of the combination of dapagliflozin with warfarin, and the combination of dapagliflozin with digoxin in healthy subjects
Full Information
NCT ID
NCT00904176
First Posted
May 18, 2009
Last Updated
October 14, 2016
Sponsor
AstraZeneca
Collaborators
Bristol-Myers Squibb
1. Study Identification
Unique Protocol Identification Number
NCT00904176
Brief Title
Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects
Official Title
Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
August 2009 (Actual)
Study Completion Date
August 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
Collaborators
Bristol-Myers Squibb
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is determine that Dapagliflozin has no effect on the pharmacokinetics (PK) or pharmacodynamics (PD) of warfarin when dapagliflozin is coadministered with warfarin. Also, that Dapagliflozin has no effect on the PK of digoxin when dapagliflozin is coadministered with digoxin.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Dapagliflozin + Warfarin
Arm Type
Active Comparator
Arm Title
Warfarin
Arm Type
Active Comparator
Arm Title
Dapagliflozin + Digoxin
Arm Type
Active Comparator
Arm Title
Digoxin
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Dapagliflozin
Intervention Description
Tablets, Oral, 20 mg, followed by 10 mg, Single Dose
Intervention Type
Drug
Intervention Name(s)
Warfarin
Other Intervention Name(s)
Coumadin
Intervention Description
Tablets, Oral, 25 mg, Single Dose
Intervention Type
Drug
Intervention Name(s)
Digoxin
Other Intervention Name(s)
Lanoxin
Intervention Description
Tablets, Oral, 0.25, Single Dose
Primary Outcome Measure Information:
Title
Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs
Time Frame
216 hours post-dose
Secondary Outcome Measure Information:
Title
To assess the effect of dapagliflozin on the PK of R-warfarin, when warfarin and dapagliflozin are coadministered in healthy subjects (Cohort 1)
Time Frame
16 time points
Title
To assess the safety and tolerability of the combination of dapagliflozin with warfarin, and the combination of dapagliflozin with digoxin in healthy subjects
Time Frame
16 time points
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
Body Mass Index (BMI) of 18 to 32 kg/m², inclusive. BMI = weight (kg)/ [height (m)]²
Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) and men, ages 18 to 45
Exclusion Criteria:
WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal
Any significant acute or chronic medical illness or relevant trauma (e.g. history of chronic hypertension, bacterial endocarditis, hemorrhagic stroke, motor vehicle accident resulting in significant head trauma or internal injuries)
History of important arrhythmias as determined by the Investigator, including but not limited to ventricular fibrillation, ventricular tachycardia, A-V block, Wolff-Parkinson-White Syndrome, and sinus bradycardia (defined in this study as heart rate < 50 bpm based on vital signs and ECG performed within 21 days of Study Day 1)
History or evidence of abnormal bleeding or coagulation disorder (e.g., history of prolonged bleeding during dental procedures, pregnancy delivery, previous surgery or injury) and/or having a first degree relative under 50 years of age with a history of abnormal bleeding or coagulation disorder per patient's report
History of unexplained syncope
Presence of external hemorrhoids with signs of rectal bleeding on physical exam
Positive fecal occult blood (FOB), using the Hemoccult Sensa® assay (or equivalent), or hematuria (more than trace), unless deemed not clinically significant by the Investigator and Medical Monitor at screening or dosing
Platelet count < 150,000 cells/µL at screening or dosing
INR or aPTT values above the upper limit of normal (ULN) at screening or dosing
Hemoglobin or hematocrit < LLN at screening or dosing
Abnormal urinalysis at screening or dosing (repeat urinalysis may be allowed for positive hematuria in women)
Glucosuria at screening or dosing
Abnormal liver functions tests (ALT, AST or total bilirubin > 10% above ULN) at screening or dosing
History of diabetes mellitus
History of heart failure
History of renal insufficiency
History of recurrent (defined as 3 occurrences per year) or recent vulvovaginal mycotic infections
Positive urine screen for drugs of abuse either at screening or before dosing
Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1, -2 antibody
Protein C or Protein S deficiency
History of allergy to SGLT2 inhibitors or related compounds
History of allergy to warfarin or related compounds
History of allergy to digoxin or related compounds
Prior exposure to dapagliflozin within 3 months of Day -1
Exposure to any investigational drug or placebo within 4 weeks of Day -1
Use of any prescription drugs within or over-the-counter acid controllers or vitamin K containing products within 4 weeks prior to study drug administration
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
Pra International
City
Lenexa
State/Province
Kansas
ZIP/Postal Code
66219
Country
United States
12. IPD Sharing Statement
Links:
URL
http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3648&filename=MB102-058_redacted%20_CSR%20_synopsis.pdf
Description
MB102-058_redacted _CSR _synopsis
Learn more about this trial
Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects
We'll reach out to this number within 24 hrs